- Abstract:
-
Several oncogenic factors have been involved in prostate cancer progression. However, therapeutic approaches still focus on suppression of androgen receptor (AR) signaling. In fact, whereas the full-length AR incorporates a ligand-binding domain, which has become a drug target for competitive inhibitors, other transcription factors often do not have tractable binding pockets that aid drug development. Consequently drug development efforts have turned to transcription co-regulators, often chro...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Publisher:
- Elsevier Publisher's website
- Journal:
- Molecular and cellular endocrinology Journal website
- Publication date:
- 2017-06-05
- Acceptance date:
- 2017-06-08
- DOI:
- EISSN:
-
1872-8057
- ISSN:
-
0303-7207
- Pubs id:
-
pubs:817467
- URN:
-
uri:710b52a7-ef4a-4ffc-910e-7a22979e1441
- UUID:
-
uuid:710b52a7-ef4a-4ffc-910e-7a22979e1441
- Local pid:
- pubs:817467
- Copyright date:
- 2017
Journal article
Bromodomain-containing proteins in prostate cancer.
Actions
Authors
Funding
South-East Norway Health Authorities
More from this funder
Norwegian Centre for Molecular Medicine
More from this funder
Southern and Eastern Norway Regional Health Authority
More from this funder
Norwegian Research Council
More from this funder
Expand funders...
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record